PSTI Pluristem Therapeutics Inc.

1.46
+0.04  (3%)
Previous Close 1.42
Open 1.44
Price To book 4.71
Market Cap 142311532
Shares 97,473,652
Volume 1,005,250
Short Ratio 4.46
Av. Daily Volume 372,386

SEC filingsSee all SEC filings

  1. 8-K - Current report 171089949
  2. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 171074024
  3. 8-K - Current report 171043176
  4. 424B5 - Prospectus [Rule 424(b)(5)] 17953875
  5. 8-K - Current report 17953873

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment to commence 1H 2017.
PLX-PAD (stem cells)
Critical limb ischemia (CLI)
Phase 2 put on clinical hold Jun 2013. Lifted Sept 2013. Enrollment completed May 2016. Data are due late 2017.
PLX-PAD (stem cells)
Intermittent claudication, or IC

Latest News

  1. Corporate News Blog - Nabriva Therapeutics Declares Positive Top-line Results from Phase-3 Clinical Trial Evaluating Lefamulin for the Treatment of CABP
  2. Pluristem's Ischemia Candidate Gets Fast Track Designation
  3. Biotech Stocks Surging in September
  4. Pluristem Wins Key FDA Approval
  5. UPDATE: Pluristem stock jumps 21% premarket after FDA grants CLI treatment fast-track designation
  6. U.S. FDA Grants Fast Track Designation to Pluristem's PLX-PAD for the Treatment of Critical Limb Ischemia (CLI)
  7. Pluristem Strengthens Its Position in Asia, Awarded Two New Patents in Hong Kong for Critical Limb Ischemia and Muscle Regeneration
  8. Pluristem Reports Fourth Quarter and Fiscal 2017 Corporate and Financial Highlights
  9. Should You Buy Pluristem Therapeutics Inc (PSTI)?
  10. $8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program
  11. Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Pluristem Therapeutics
  12. These Are the Hottest Stocks on the Planet Wednesday: URBN, TGT, PSTI, CSCO
  13. Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis
  14. U.S. Department of Defense to Conduct Studies of Pluristem’s PLX-R18 in a New ARS Project for Use Before Radiation Exposure
  15. Israeli Government to Support Pluristem’s Marketing Activity in China – Ministry of Economy Awards Company “Smart Money” Grant
  16. Today's Research Reports on Trending Tickers: Biogen Inc. and Pluristem Therapeutics Inc.
  17. Pluristem stock rises 2.5% on mid-stage clinical trial results
  18. New Data from ARS Study Shows Significant Hematological Deficiencies Even at Low Radiation Levels; PLX-R18 Supports Hematological Recovery
  19. This new drug could help the U.S. survive a nuclear meltdown
  20. Pluristem Advances its Multinational Phase III Critical Limb Ischemia Study, Targeting Initiation at 40 Active Sites by the End of 2017

SEC Filings

  1. 8-K - Current report 171089949
  2. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 171074024
  3. 8-K - Current report 171043176
  4. 424B5 - Prospectus [Rule 424(b)(5)] 17953875
  5. 8-K - Current report 17953873
  6. EFFECT - Notice of Effectiveness 17943882
  7. S-3 - Registration statement under Securities Act of 1933 17926420
  8. 8-K - Current report 17926372
  9. 8-K - Current report 17920998
  10. 8-K - Current report 17870044